https://www.roche.com/investors/updates/inv-update-2022-12-12c
Roche presents new data demonstrating the potential benefit of glofitamab and Lunsumio as...
Data showcase the potential of glofitamab and Lunsumio to address diverse patient needsData presented at ASH 2022 and simultaneously published in the New...
https://www.dana-farber.org/clinical-trials/24-104
Pilot Study of Glofitamab and Lenalidomide in Patients with Relapsed or Refractory Mantle Cell...
The purpose of this study is to find out whether the combination of glofitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle...
https://www.hmpgloballearningnetwork.com/site/frmc/news/patient-outcomes-after-epcoritamab-or-glofitamab-failure-relapsed-or-refractory-lbcl
Patient Outcomes After Epcoritamab or Glofitamab Failure in R/R LBCL
Disease progression after treatment with bispecific antibodies such as glofitamab in relapsed or refractory large B-cell lymphoma (R/R LBCL) is associated with...
patient outcomesepcoritamabglofitamabfailure
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-03768&r=1
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With...
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
https://www.medicines.org.uk/emc/ingredient/3426
Medicines containing the active ingredient glofitamab - (emc)
Medicines containing the active ingredient glofitamab
the activemedicinescontainingingredientglofitamab
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-04692&r=1
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and...
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell...
a studyevaluateglofitamabmonotherapychemoimmunotherapy
https://www.cancerresearchuk.org/about-cancer/treatment/drugs/glofitamab
Glofitamab (Columvi) | Cancer Research UK
Glofitamab is a type of targeted cancer drug. It's a treatment for certain types of non-Hodgkin lymphoma (NHL). Find out more.
cancer researchglofitamabcolumviuk
https://www.roche.com/media/releases/med-cor-2022-12-12c
Roche presents new data demonstrating the potential benefit of glofitamab and Lunsumio as...
Data showcase the potential of glofitamab and Lunsumio to address diverse patient needsData presented at ASH 2022 and simultaneously published in the New...
https://www.roche.com/investors/updates/inv-update-2020-06-12
Roche presents updated data on novel CD20xCD3 bispecific cancer immunotherapy glofitamab in people...
Results from the phase I NP30179 study show durable complete responses with glofitamab in patients with aggressive and indolent lymphomas after a median of...